These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22440894)

  • 1. Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.
    Colovic N; Suvajdzic N; Kraguljac Kurtovic N; Djordjevic V; Dencic Fekete M; Drulovic J; Vidovic A; Tomin D
    Biomed Pharmacother; 2012 Apr; 66(3):173-4. PubMed ID: 22440894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
    Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
    Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
    Ellis R; Boggild M
    Mult Scler; 2009 Apr; 15(4):505-8. PubMed ID: 19251838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone-related acute leukemia in two MS patients.
    Pielen A; Goffette S; Van Pesch V; Gille M; Sindic CJ
    Acta Neurol Belg; 2008 Sep; 108(3):99-102. PubMed ID: 19115673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
    Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
    Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
    Ramkumar B; Chadha MK; Barcos M; Sait SN; Heyman MR; Baer MR
    Cancer Genet Cytogenet; 2008 Apr; 182(2):126-9. PubMed ID: 18406875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients.
    Voltz R; Starck M; Zingler V; Strupp M; Kolb HJ
    Mult Scler; 2004 Aug; 10(4):472-4. PubMed ID: 15327049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
    Le Page E; Leray E; Edan G;
    Mult Scler; 2011 Jul; 17(7):867-75. PubMed ID: 21325016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
    Ellis R; Brown S; Boggild M
    Mult Scler; 2015 Apr; 21(5):642-5. PubMed ID: 25013152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy-related acute nonlymphoblastic leukemia following mitoxantrone therapy in a patient with multiple sclerosis.
    Sumrall A; Dreiling B
    J Miss State Med Assoc; 2007 Jul; 48(7):206-7. PubMed ID: 17939254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.
    Sadiq SA; Rammal M; Sara G
    Mult Scler; 2008 Mar; 14(2):272-3. PubMed ID: 17986509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone-related acute leukemia in MS: an open or closed book?
    Chan A; Lo-Coco F
    Neurology; 2013 Apr; 80(16):1529-33. PubMed ID: 23589639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.
    Ko MW; Tamhankar MA; Volpe NJ; Porter D; McGrath C; Galetta SL
    J Neurol Sci; 2008 Oct; 273(1-2):144-7. PubMed ID: 18687447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia].
    Meyer C; Ansorge N; Siglienti I; Salmen S; Stroet A; Nückel H; Dührsen U; Ritter PR; Schmidt WE; Gold R; Chan A
    Nervenarzt; 2010 Dec; 81(12):1483-9. PubMed ID: 21079910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.
    Brassat D; Recher C; Waubant E; Le Page E; Rigal-Huguet F; Laurent G; Edan G; Clanet M
    Neurology; 2002 Sep; 59(6):954-5. PubMed ID: 12297591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mitoxantrone].
    Pericot I; Montalban X
    Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation.
    Ottone T; Hasan SK; Montefusco E; Curzi P; Mays AN; Chessa L; Ferrari A; Conte E; Noguera NI; Lavorgna S; Ammatuna E; Divona M; Bovetti K; Amadori S; Grimwade D; Lo-Coco F
    Genes Chromosomes Cancer; 2009 Mar; 48(3):213-21. PubMed ID: 19023877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients.
    Hellwig K; Schimrigk S; Lukas C; Hoffmann V; Brune N; Przuntek H; Müller T
    Clin Neuropharmacol; 2006; 29(5):286-91. PubMed ID: 16960474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
    J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.